BRAF and melanoma: In contrast, IHC analyses of BRAFV600E protein with the use of the BRAFV600E mutant-specific monoclonal antibody, VE1, in general, revealed an intense and homogeneous staining of BRAFV600E and hardly any evidence of intratumor and/or intrapatient heterogeneity.13,14,17–19,28,29 Moreover, Colombino et al25 assessed intrapatient heterogeneity of mutated BRAF/NRAS and revealed that 84 of 99 (85%) patients who had paired samples of primary and secondary melanomas showed consistent mutation patterns between primary tumors and metastatic lesions.